NASDAQ:CUR - Neuralstem Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.5164 -0.02 (-3.73 %)
(As of 11/18/2018 02:57 AM ET)
Previous Close$0.5164
Today's Range$0.5030 - $0.5615
52-Week Range$0.48 - $3.09
Volume79,520 shs
Average Volume399,847 shs
Market Capitalization$7.76 million
P/E RatioN/A
Dividend YieldN/A
Beta2.01
Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Receive CUR News and Ratings via Email

Sign-up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CUR
Previous Symbol
CUSIPN/A
Phone301-366-4841

Debt

Debt-to-Equity RatioN/A
Current Ratio10.41
Quick Ratio10.41

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$260,000.00
Price / Sales30.11
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book0.92

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-15,660,000.00
Net Margins-1,783.78%
Return on Equity-111.81%
Return on Assets-68.57%

Miscellaneous

Employees6
Outstanding Shares15,160,000
Market Cap$7.76 million
OptionableOptionable

Neuralstem (NASDAQ:CUR) Frequently Asked Questions

What is Neuralstem's stock symbol?

Neuralstem trades on the NASDAQ under the ticker symbol "CUR."

How were Neuralstem's earnings last quarter?

Neuralstem, Inc. (NASDAQ:CUR) issued its quarterly earnings data on Wednesday, November, 14th. The company reported ($0.12) earnings per share for the quarter. Neuralstem had a negative return on equity of 111.81% and a negative net margin of 1,783.78%. View Neuralstem's Earnings History.

When is Neuralstem's next earnings date?

Neuralstem is scheduled to release their next quarterly earnings announcement on Monday, April 1st 2019. View Earnings Estimates for Neuralstem.

What price target have analysts set for CUR?

0 equities research analysts have issued 12-month price targets for Neuralstem's shares. Their predictions range from $1.91 to $1.91. On average, they anticipate Neuralstem's stock price to reach $1.91 in the next twelve months. This suggests a possible upside of 269.9% from the stock's current price. View Analyst Price Targets for Neuralstem.

Has Neuralstem been receiving favorable news coverage?

Media coverage about CUR stock has been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Neuralstem earned a news impact score of 0.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the next few days.

Who are some of Neuralstem's key competitors?

Who are Neuralstem's key executives?

Neuralstem's management team includes the folowing people:
  • Mr. James B. Scully, Interim CEO & Principal Accounting Officer (Age 56)
  • Dr. Karl Y. Johe Ph.D., Co-Founder & Chief Scientific Officer (Age 58)
  • Dr. Thomas G. Hazel Ph.D., Sr. VP of Research
  • Dr. David P. Recker, Chief Medical Officer (Age 60)

How do I buy shares of Neuralstem?

Shares of CUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neuralstem's stock price today?

One share of CUR stock can currently be purchased for approximately $0.5164.

How big of a company is Neuralstem?

Neuralstem has a market capitalization of $7.76 million and generates $260,000.00 in revenue each year. Neuralstem employs 6 workers across the globe.

What is Neuralstem's official website?

The official website for Neuralstem is http://www.neuralstem.com.

How can I contact Neuralstem?

Neuralstem's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 301-366-4841 or via email at [email protected]


MarketBeat Community Rating for Neuralstem (NASDAQ CUR)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  225 (Vote Outperform)
Underperform Votes:  194 (Vote Underperform)
Total Votes:  419
MarketBeat's community ratings are surveys of what our community members think about Neuralstem and other stocks. Vote "Outperform" if you believe CUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel